Clinical Trials for Olema Pharmaceuticals

Explore 5 clinical trials worldwide

Showing 1-5 of 5 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Olema Pharmaceuticals

Clinical Trials (5)

NCT07085767
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
PHASE3Not yet recruiting
1,000 participants
Started: Oct 31, 2025 · Completed: Jan 31, 2032
5 conditions2 sponsors10 locations
NCT06784193
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
PHASE1Recruiting
180 participants
Started: Dec 16, 2024 · Completed: Aug 30, 2027
6 conditions1 sponsor8 locations
NCT06016738
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
PHASE3Recruiting
510 participants
Started: Nov 16, 2023 · Completed: Sep 30, 2027
5 conditions1 sponsor193 locations
NCT05508906
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
PHASE1Recruiting
190 participants
Started: Aug 31, 2022 · Completed: Jan 31, 2028
5 conditions3 sponsors16 locations
NCT05266105
A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
PHASE1Active, not recruiting
60 participants
Started: Dec 10, 2021 · Completed: Jul 31, 2025
1 condition2 sponsors8 locations